Nonprofit issues challenge to accelerate treatments for every person with CF
Oct. 30, 2019
|
5 min read
This medicine represents the single greatest therapeutic advancement in the history of CF, offering a treatment for the underlying cause of the disease that could eventually benefit more than 90 percent of people with CF.
Oct. 21, 2019
|
3 min read
Preston W. Campbell, III, President and CEO to retire; Michael P. Boyle, MD, appointed as successor effective January 2020.
May 21, 2019
|
4 min read